October 2026

Why the exact change in your CLRN1 gene matters, and what researchers are studying for each group.

If you have Usher syndrome type 3A, you may have heard the term N48K. You may also have seen news about a drug for Usher syndrome type 3 and wondered if it applies to you. The answer depends on the exact change in your CLRN1 gene. This article explains what N48K means, how it differs from other CLRN1 changes, and where research stands for each group.

What is CLRN1?
CLRN1 is the gene behind Usher syndrome type 3A. It holds the instructions for a protein called clarin-1. Clarin-1 helps the hair cells in your inner ear turn sound into signals your brain can read. It also plays a role in keeping the retina healthy. When CLRN1 is affected by a genetic change called a mutation or variant, hearing and vision slowly decline over time. That gradual pattern is a hallmark of Usher type 3.

Scientists have found many different genetic changes in CLRN1. Each one is called a variant, a specific change in the spelling of a gene. Your genetic test report should list which variant, or variants, you have.

What Makes N48K Different?
N48K is the CLRN1 variant researchers have studied most. It is the most common CLRN1 variant in North America, and it is especially common among people of Ashkenazi Jewish heritage. In Finland, a different variant, called Y176X, is the most common.

Here is why the difference matters. With N48K, your body still makes clarin-1. But the protein does not fold into the right shape. Think of it like a key that is slightly bent. The cell sees the bent protein as faulty and breaks it down before it can reach its job site. So, the protein is made, but it does not last.

Many other variants, including Y176X, work differently. They cut the instructions short, so the body makes little or no working clarin-1 at all. That is more like having no key in the first place. Additional variants fall somewhere in between.

This difference determines which treatments might work. A bent key might be straightened. A missing key has to be replaced.

The N48K Path: A Drug That Steadies the Protein
For people with N48K, researchers are developing a small molecule, a drug made from a small chemical compound that can be taken by mouth. It is called BF844. It is designed to help the bent clarin-1 protein hold its shape, so the cell does not throw it away.

Researchers at Case Western Reserve University reported BF844 in 2016. In mice with the N48K variant, it slowed hearing loss and prevented deafness. The Usher III Initiative, a nonprofit started by families, has led the effort to bring it to affected patients.

In October 2024, BF844 entered its first human trial in Perth, Australia. It was the first clinical trial ever for an Usher syndrome type 3 treatment. This Phase 1 trial tested safety in healthy volunteers, not in people with Usher syndrome. The Usher III Initiative reports that BF844 was safe and well tolerated. The next step is a Phase 2 trial in people with USH3A, to learn whether the drug actually slows hearing or vision loss. Before that can begin, the team needs to scale up manufacturing, turn the drug into a capsule, and finish longer safety studies. They have begun talks with the FDA and are seeking funding and a partner for Phase 2.

To prepare, Foundation Fighting Blindness and the Usher III Initiative launched a natural history study, a study that tracks how a condition changes over time without treatment. It follows up to 20 people with N48K over four years and measures both hearing and vision. This helps researchers learn when treatment may work best and how to tell if it is working.

One important note: BF844 was built for N48K. Because it works by steadying a protein that is already there, it is not expected to help variants where little or no protein is made. Whether it could help other variants that also cause a misshapen protein has not been evaluated in people.

The Non-N48K Path: Replacing the Gene
If you have a different CLRN1 variant, the main research path right now is gene therapy, a treatment that delivers a healthy copy of a gene to the cells that need it. Most gene therapies use a harmless virus, called AAV, as a delivery vehicle. Because it replaces the gene itself, gene therapy could, in principle, help people with any CLRN1 variant, including N48K.

For hearing, several mouse studies have shown promise. A 2017 study from Case Western found that delivering CLRN1 into the inner ear of young mice maintained their hearing well into adulthood. A 2019 study used a different delivery virus to restore hearing in mice and also reached hair cells in primates. A clear lesson from this work is treatment timing. Gene therapy worked best before hair cells were lost.

For vision, research has taken a surprising turn. Scientists long assumed clarin-1 mattered most in the photoreceptors, the light-sensing cells of the retina. Newer studies point somewhere else: Müller glia, support cells that stretch across the retina and help keep photoreceptors healthy. A 2025 zebrafish study from the University of Florida found that adding clarin-1 back into Müller glia, not photoreceptors, protected the retina from damage. It also found that too much clarin-1 caused harm, so the dose will need to be just right. Two 2026 studies, one in mice and one in lab-grown mini retinas, support the same idea. This matters because a gene therapy has to reach the right cells to work.

Recent Research

The studies below cover both N48K and non-N48K work. 

April 2016, Nature Chemical Biology. Case Western researchers reported BF844, the first drug designed to steady the N48K version of clarin-1. In N48K mice, it slowed hearing loss and prevented deafness.

October 2017, Scientific Reports. Gene therapy kept hearing working in mice that lacked clarin-1, when given early in life. Including extra control sections of the gene made the treatment work far better.

August 2024, Foundation Fighting Blindness and Usher III Initiative. A four-year natural history study for people with N48K launched within the Foundation’s larger Uni-Rare study, at sites in the U.S., Europe, and beyond.

October 2024, Perth, Australia. The first-ever clinical trial for an Usher type 3 treatment began, testing BF844 for safety in healthy volunteers.

March 2025, PLOS Genetics. A University of Florida zebrafish study found that clarin-1 does its key retinal work in Müller glia. This could change how future retinal gene therapies are designed.

January 2026, Advanced Science. A team led by Institut Pasteur found that clarin-1 and a related protein, clarin-2, back each other up in the inner ear. Mice missing both had much worse hearing than mice missing just one. This may help explain why people with the same CLRN1 variant can have very different hearing. The authors suggest adding the CLRN2 gene to genetic testing for Usher type 3.

February 2026, Usher III Initiative update. BF844 was reported safe and well tolerated in its Phase 1 trial. Planning for a Phase 2 trial in people with USH3A is underway, pending funding and a partner.

2026, Investigative Ophthalmology & Visual Science. A new study adds to the evidence that clarin-1 is made mainly in Müller glia, and that photoreceptors are harmed indirectly when it is missing. The full article is free to read on PubMed Central.

2026, CNS Neuroscience & Therapeutics. Researchers grew mini retinas in the lab to study CLRN1 variants. They found the variants disrupted the energy centers, called mitochondria, inside Müller cells.

Know Your Variant

The most useful step you can take right now is to know your exact CLRN1 variant. Look at your genetic test report. N48K may be listed as p.Asn48Lys or c.144T>G. If your report is hard to read, a genetic counselor can walk you through it. If you have never had genetic testing, ask your care team about it.

Next, make sure researchers can find you. Update your USH Trust profile with your Usher subtype. Consider joining the Usher Syndrome Data Collection Program, powered by RARE-X, and uploading your genetic report. Future trials, whether for BF844 or for gene therapy, will look for people with specific variants. Being findable means you hear about opportunities that fit you.

Usher type 3A research is not one-size-fits-all, and that is a good thing. It means scientists are learning to match treatments to the way each variant works. Some paths are further along than others, and none has reached patients as an approved treatment yet. But both paths are moving, and your information helps move them forward.

This article is for general information and community awareness. It isn’t medical advice. Please talk with your own care team and a genetic counselor about what’s right for you.